Toluidine blue staining of murine mast cells and quantitation by a novel, automated image analysis method using whole slide skin images.

Mast cells are immune cells of myeloid lineage, characterized by the presence of cytoplasmic granules. These cells play a significant role in multiple pathologies, such as urticaria and type 1 hypersensitivity reactions. Mast cells in tissue sections can be demonstrated with metachromatic stains, such as toluidine blue. Metachromatic staining of mast cells is influenced by the type of mast cell, pH of the staining solution and fixative employed. The objective of this study is to identify a simple, consistent, and reproducible toluidine blue staining method to quantify the mast cells in whole slide skin images using automated image analysis. Skin sections from naive mice and atopic dermatitis mice were stained with toluidine blue methods by Churukian-Schenk and Luna. Luna's toluidine blue staining method without the eosin counterstaining provided optimal staining of mast cells with a greater contrast to the background. The Churukian-Schenk toluidine blue method resulted in slight background staining which confounded the accurate detection and quantification of mast cells in mouse skin sections using an automated image analysis algorithm. Using the Luna toluidine blue stain, a 5-fold increase in the total number of mast cells was observed in atopic dermatitis skin samples as compared to naive mice. In summary, a simple, conventional, and reproducible toluidine blue method was identified to quantify the mast cells in mouse skin sections using an automated image analysis algorithm.

TGFß2 and TGFß3 mediate appropriate context-dependent phenotype of rat valvular interstitial cells.

This study focused on characterizing the potential mechanism of valvular toxicity caused by TGFß receptor inhibitors (TGFßRis) using rat valvular interstitial cells (VICs) to evaluate early biological responses to TGFßR inhibition. Three TGFßRis that achieved similar exposures in the rat were assessed. Two dual TGFßRI/-RII inhibitors caused valvulopathy, whereas a selective TGFßRI inhibitor did not, leading to a hypothesis that TGFß receptor selectivity may influence the potency of valvular toxicity. The dual valvular toxic inhibitors had the most profound effect on altering VIC phenotype including altered morphology, migration, and extracellular matrix production. Reduction of TGFß expression demonstrated that combined TGFß2/ß3 inhibition by small interfering RNA or neutralizing antibodies caused similar alterations as TGFßRis. Inhibition of TGFß3 transcription was only associated with the dual TGFßRis, suggesting that TGFßRII inhibition impacts TGFß3 transcriptional regulation, and that the potency of valvular toxicity may relate to alteration of TGFß2/ß3-mediated processes involved in maintaining proper balance of VIC phenotypes in the heart valve.

Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.

IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket. This has resulted in the identification of compounds such as 12 with improved potency and selectivity. Additionally 12 demonstrated activity in a pharmacokinetics/pharmacodynamics (PK/PD) model. Further optimization efforts led to the identification of the highly kinome selective 21, which demonstrated a robust PD effect and efficacy in a TLR7 driven model of murine psoriasis.

Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFßR1 Inhibitor as an Immuno-oncology Agent.

Novel imidazole-based TGFßR1 inhibitors were identified and optimized for potency, selectivity, and pharmacokinetic and physicochemical characteristics. Herein, we report the discovery, optimization, and evaluation of a potent, selective, and orally bioavailable TGFßR1 inhibitor, 10 (BMS-986260). This compound demonstrated functional activity in multiple TGFß-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models. Since daily dosing of TGFßR1 inhibitors is known to cause class-based cardiovascular (CV) toxicities in preclinical species, a dosing holiday schedule in the anti-PD-1 combination efficacy studies was explored. An intermittent dosing regimen of 3 days on and 4 days off allowed mitigation of CV toxicities in one month dog and rat toxicology studies and also provided similar efficacy as once daily dosing.